Feeling Cold on a GLP-1 Microdose: Body Temperature, Thermogenesis, and What Actually Changed

A woman six weeks into a low-dose tirzepatide protocol starts wearing a cardigan in an office that has not changed its thermostat. Her hands are cold by mid-afternoon most days. Her colleagues are in short sleeves. She checks the prescribing information and finds nothing about cold, searches online, and finds thousands of people describing exactly what she feels. The medication is involved. It is involved through the meal she stopped eating at 1 pm.

Feeling cold is one of the most consistently reported experiences on semaglutide and tirzepatide and one of the least discussed in the clinical literature, because it is not a direct pharmacological effect and does not appear as an adverse reaction in the trial tables. What the trials did measure, in detail, is how much less people eat and how much fat they lose. Thermoregulation research going back decades explains what those two changes do to heat production and heat retention, and the explanation is complete enough that the cold feeling is close to predictable.

This article covers the four mechanisms that reduce warmth on a GLP-1 protocol, what a microdose changes about each, the paradoxical evidence that GLP-1 receptor agonists activate brown fat, the two deficiencies that produce the same symptom and need testing, and a triage table that separates the cold feeling that a sandwich fixes from the one that needs a clinician.

Why do people feel cold on a GLP-1 medication?

People feel cold on a GLP-1 medication because the body produces less heat when it eats less, retains less heat when it carries less fat, and diverts blood away from the skin when energy is scarce. None of those is a pharmacological action of semaglutide or tirzepatide on temperature regulation. All three are predictable consequences of the energy deficit and fat loss the medication produces, which is why the cold feeling tracks the size of the deficit rather than the size of the dose.

The prescribing information supports that reading. The Wegovy label lists nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, and several others at rates of 5 percent or more. Cold intolerance, chills, and feeling cold do not appear in the common adverse reaction table for semaglutide 2.4 mg, and the Zepbound label for tirzepatide is the same. A symptom that thousands of people report but that did not separate from placebo in trials of more than 2,000 participants is most likely a feature of the weight loss those trials produced in both arms, amplified in the treatment arm because it lost far more weight.

Human heat production has three sources. Resting metabolism accounts for 60 to 70 percent of daily energy expenditure in a sedentary adult and is the base heat load. Physical activity accounts for most of the rest. Diet-induced thermogenesis, the energy spent digesting, absorbing, and storing food, accounts for roughly 10 percent of intake, and it is the first casualty of a GLP-1 protocol because it disappears with every meal that is skipped or shrunk. The next four sections take each mechanism in turn, and the table at the end matches the pattern of cold to its most likely cause.

How much heat does eating less remove?

Eating 800 fewer calories a day removes about 80 calories of heat from diet-induced thermogenesis alone, and the loss is concentrated in the hours after the meals that no longer happen. Westerterp reviewed the thermic effect of food in 2004 and put it at roughly 10 percent of total intake on a mixed diet, with a strong dependence on composition: protein releases 20 to 30 percent of its energy as heat during processing, carbohydrate 5 to 10 percent, and fat 0 to 3 percent. Alcohol sits between 10 and 30 percent. The heat arrives over two to four hours after eating, which is why a mid-afternoon chill so often follows a missed lunch.

A GLP-1 medication cuts intake hard. Friedrichsen and colleagues reported in 2021 that semaglutide 2.4 mg reduced ad libitum energy intake by about 35 percent, and Blundell and colleagues found a 24 percent reduction at 1.0 mg in 2017. On a baseline of 2,400 kcal, those figures correspond to 560 to 840 fewer calories a day. A microdose, by definition, produces a smaller effect, somewhere in the range of 300 to 500 fewer calories for most people, which is one reason cold intolerance is usually milder on a microdose than at full dose. The heat loss scales with the food not eaten, not with the milligrams injected.

Composition matters as much as quantity. A person who keeps protein at 1.2 to 1.6 g per kilogram of body weight while eating less loses much less diet-induced heat than a person whose reduced appetite lands mostly on protein, because protein carries three to four times the thermic effect of carbohydrate. The practical implication is one of the better-supported findings in this area: a 30 g protein meal eaten on schedule, regardless of appetite, is the closest thing to a heater a GLP-1 protocol offers.

Does weight loss lower resting heat production and core temperature?

Yes, and by more than the lost tissue explains. Leibel, Rosenbaum, and Hirsch published the defining study in the New England Journal of Medicine in 1995: after a 10 percent weight loss, total daily energy expenditure fell by roughly 300 kcal a day beyond what the reduction in body mass predicted, in both formerly obese and never-obese participants. Rosenbaum and Leibel later showed that this adaptive thermogenesis persisted for at least a year of weight maintenance and was driven by lower sympathetic nervous system activity, lower circulating T3, and lower leptin. Each of those reduces the heat that resting tissue produces.

The temperature consequence has been measured directly. In the CALERIE trial reported by Heilbronn and colleagues in JAMA in 2006, six months of 25 percent calorie restriction lowered 24-hour core body temperature by about 0.2 degrees Celsius, alongside a fall in fasting insulin and a reduction in energy expenditure larger than the loss of tissue predicted. Soare and colleagues reported in 2011 that people practising long-term calorie restriction had a core temperature roughly 0.2 degrees lower than both a usual-diet comparison group and a group of endurance runners matched for leanness, which separates the effect of the energy deficit from the effect of simply being lean.

Two-tenths of a degree sounds trivial and is not. Core temperature is defended within a narrow range, and a sustained shift of that size reflects a body that has reset its energy budget downward. The subjective feeling of cold is usually stronger than the number suggests because it is driven by skin temperature, not core temperature, and skin temperature falls further when the body constricts peripheral blood vessels to protect a core it is producing less heat to maintain. A microdose produces a smaller deficit and therefore a smaller adaptive response, but the direction is the same, and the effect accumulates as weight comes off.

How much does losing fat change how cold you feel?

Losing subcutaneous fat removes insulation, and the effect is large enough to measure and permanent for as long as the fat stays off. Adipose tissue has a thermal conductivity of about 0.21 watts per metre-kelvin, compared with roughly 0.49 for muscle and 0.52 for blood, according to the tissue property tables compiled by Duck in 1990. Fat conducts heat away from the core at less than half the rate of the tissues beneath it, which is exactly why mammals in cold water carry it under the skin. A person who loses two centimetres of subcutaneous fat over the trunk has lost a meaningful fraction of their passive insulation.

Keatinge established the human evidence in the 1960s with cold water immersion studies showing that skinfold thickness predicted how quickly core temperature fell, and later work by Toner, McArdle, and colleagues in the 1980s confirmed that body fat percentage was the dominant predictor of thermal balance in cool water once body size was accounted for. On dry land in an office the gradient is far gentler, but the principle holds. Heat leaves a leaner body faster, and the body responds by narrowing the blood vessels in the hands, feet, and skin to slow the loss, which is what makes the extremities the first place cold is felt.

The insulation change also explains why the cold feeling from fat loss behaves differently from the cold feeling from a missed meal. Diet-induced heat returns within an hour of eating. Insulation does not return unless the fat does. Someone 15 kilograms lighter than a year ago will feel a cool room more sharply than they used to for as long as they remain 15 kilograms lighter, and the body's set point for comfortable ambient temperature shifts up by a degree or two to match. That is an adjustment rather than a problem, and most people stop noticing it within a few months of stable weight.

Why does leptin matter for feeling cold?

Leptin is the hormone that tells the brain how much energy is stored and how much is coming in, and it falls faster than fat does when intake drops, taking heat production with it. Fat cells release leptin in proportion to their size and to recent food intake, and the intake signal dominates in the short term. Weigle and colleagues showed in 1997 that plasma leptin fell by more than half after three days of fasting, long before any meaningful fat was lost. On a GLP-1 medication the drop is gentler but sustained, and within a few weeks leptin has typically fallen 30 to 50 percent, well ahead of the loss in fat mass.

Low leptin is read by the hypothalamus as a signal of scarcity, and the response is to conserve. Sympathetic drive to brown fat and to the thyroid axis falls, active T3 falls, and resting energy expenditure falls with it. Rosenbaum and colleagues demonstrated the causal link in the Journal of Clinical Investigation in 2005: when weight-reduced people were given leptin to restore their pre-loss levels, the reductions in energy expenditure, sympathetic tone, and thyroid hormone largely reversed, even though body weight did not change. Much of adaptive thermogenesis, in other words, is a leptin signal.

This matters for a microdose in a specific way. A smaller, steadier deficit produces a smaller and slower fall in leptin than a large one, and a protocol that keeps intake regular rather than concentrated in one meal keeps the intake component of the leptin signal more stable. Neither prevents the decline, which is intrinsic to losing fat, but both moderate it, and they are part of why a gradual protocol tends to feel less cold than an aggressive one that produces the same weight loss faster.

Do GLP-1 medications activate brown fat and make you warmer?

GLP-1 receptor agonists do activate brown fat in animals, and there is some evidence they do so in people, but the effect is far too small to offset the heat lost from eating less. Lockie and colleagues showed in Diabetes in 2012 that activating GLP-1 receptors in the brain increased sympathetic outflow to brown adipose tissue and raised its thermogenesis in mice. Beiroa and colleagues followed in 2014 with evidence that liraglutide acting in the hypothalamus stimulated brown fat heat production and the browning of white fat through AMPK signalling, and that this effect was independent of the reduction in food intake.

The human data are more modest. Janssen and colleagues reported in Metabolism in 2020 that 12 weeks of exenatide in men without diabetes increased glucose uptake by brown adipose tissue on PET imaging, which is the standard marker of brown fat activity, but did not change resting energy expenditure. The brown fat was more active and the body as a whole was not producing more heat. Adult humans carry perhaps 50 to 100 grams of active brown fat, and even fully activated it contributes on the order of tens of calories a day, against the hundreds removed by the reduced intake.

This is worth stating clearly because it comes up. The animal literature is sometimes quoted to suggest that GLP-1 medications should make people warmer, and people who feel colder conclude that something has gone wrong. Nothing has. The brown fat effect is real, small, and swamped. A person who feels cold on a GLP-1 protocol is experiencing exactly what the human energy balance predicts, and any brown fat activation is a rounding error in the other direction.

Can low iron or thyroid changes cause the cold?

Yes, and they are the two causes that need a blood test rather than a sandwich. Iron deficiency impairs thermoregulation directly. Beard and colleagues showed in the American Journal of Clinical Nutrition in 1990 that women with iron deficiency anaemia lost core temperature faster during cold exposure than iron-replete controls, produced less heat in response, and had a blunted rise in thyroid hormone, and that iron repletion corrected all three. Reduced intake on a GLP-1 medication lowers iron intake, red meat is one of the foods people most often lose appetite for, and menstruating women start with lower reserves. Ferritin below about 30 µg/L is the usual threshold for deficiency.

Thyroid hormone is the second. Calorie restriction lowers active T3 by roughly 10 to 20 percent as part of the normal adaptive response, a finding Fontana and colleagues confirmed in long-term restriction practitioners in 2006, and that reduction is one of the mechanisms behind the lower core temperature described above. This is adaptation rather than disease, and TSH usually remains normal, so it does not need treatment. What does need attention is a rise in TSH above the reference range with a low free T4, which indicates true hypothyroidism and produces the same cold intolerance for a different reason. GLP-1 medications do not cause hypothyroidism, but weight loss can change the levothyroxine dose someone already takes, and a dose that was right at a higher weight can become wrong.

The clue that separates these from ordinary energy-deficit cold is company. Cold that arrives alone, in the afternoon, after a missed meal, is thermogenesis. Cold that arrives with fatigue, hair shedding, constipation, dry skin, and brittle nails, and that persists through a properly fed day, is the cluster both iron deficiency and low thyroid function produce. That cluster is common enough on GLP-1 protocols, and the tests cheap enough, that requesting ferritin, a full blood count, TSH, and free T4 is a reasonable step rather than an anxious one.

What helps with feeling cold on a GLP-1 microdose?

Regular protein-containing meals help most, because they restore the diet-induced heat that a suppressed appetite removed, and resistance training helps next, because muscle generates most resting heat and is the tissue an energy deficit erodes if it is not defended. Fluid intake of two to three litres a day, including warm drinks, supports the blood volume that carries heat to the extremities, and thirst is blunted on these medications so it has to be deliberate. Beyond those three, layers, warm feet, and patience cover most of what remains.

Dose and pace matter too. A microdose that produces a 300 to 500 kcal deficit generates less adaptive thermogenesis, a slower leptin decline, and less muscle loss than a full dose producing 800, and the cold feeling scales accordingly. Someone who is cold most of the day, most days, has usually let intake fall further than the protocol intended, and the fix is more often a floor on calories and protein than a change to the injection. The table below matches the most common patterns to what is likely behind them and what to do about it.

The medication did not turn the heat down. The meals did.

Feeling cold on a GLP-1 protocol has a complete explanation and none of it involves the drug acting on temperature. Fewer and smaller meals remove the heat of digestion, most sharply when protein is what gets skipped. A sustained deficit lowers leptin, thyroid hormone, and sympathetic tone, and the body responds by making roughly 300 fewer calories of heat a day than its new size would predict. Fat loss strips insulation that does not come back while the weight stays off. Blood retreats from the hands and feet to protect a core that is being warmed less. Each step is documented in decades of thermoregulation research that predates GLP-1 medications entirely, and each is proportional to the deficit rather than the dose, which is why a microdose is usually the milder experience. The exceptions worth knowing are iron and thyroid, which produce the same symptom with different company, and hypoglycaemia in anyone also on insulin or a sulfonylurea, which produces a cold sweat that is not about temperature at all.

Frequently asked questions

Clinical references

1. Novo Nordisk. Wegovy (semaglutide) injection 2.4 mg: prescribing information, section 6.1, adverse reactions. US Food and Drug Administration; 2021, with subsequent revisions.
2. Eli Lilly. Zepbound (tirzepatide) injection: prescribing information, section 6.1, adverse reactions. US Food and Drug Administration; 2023, with subsequent revisions.
3. Westerterp KR. Diet induced thermogenesis. Nutrition and Metabolism. 2004;1(1):5.
4. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021;23(3):754-762.
5. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017;19(9):1242-1251.
6. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. New England Journal of Medicine. 1995;332(10):621-628.
7. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008;88(4):906-912.
8. Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. Journal of Clinical Investigation. 2005;115(12):3579-3586.
9. Heilbronn LK, de Jonge L, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA. 2006;295(13):1539-1548.
10. Soare A, Cangemi R, Omodei D, Holloszy JO, Fontana L. Long-term calorie restriction, but not endurance exercise, lowers core body temperature in humans. Aging. 2011;3(4):374-379.
11. Fontana L, Klein S, Holloszy JO, Premachandra BN. Effect of long-term calorie restriction with adequate protein and micronutrients on thyroid hormones. Journal of Clinical Endocrinology and Metabolism. 2006;91(8):3232-3235.
12. Duck FA. Physical Properties of Tissue: A Comprehensive Reference Book. London: Academic Press; 1990.
13. Keatinge WR. Survival in Cold Water: The Physiology and Treatment of Immersion Hypothermia and of Drowning. Oxford: Blackwell Scientific; 1969.
14. Toner MM, McArdle WD. Physiological adjustments of man to the cold. In: Pandolf KB, Sawka MN, Gonzalez RR, eds. Human Performance Physiology and Environmental Medicine at Terrestrial Extremes. Indianapolis: Benchmark Press; 1988:361-399.
15. Weigle DS, Duell PB, Connor WE, Steiner RA, Soules MR, Kuijper JL. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. Journal of Clinical Endocrinology and Metabolism. 1997;82(2):561-565.
16. Lockie SH, Heppner KM, Chaudhary N, et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes. 2012;61(11):2753-2762.
17. Beiroa D, Imbernon M, Gallego R, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014;63(10):3346-3358.
18. Janssen LGM, Nahon KJ, Bracké KFM, et al. Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males. Metabolism. 2020;106:154167.
19. Beard JL, Borel MJ, Derr J. Impaired thermoregulation and thyroid function in iron-deficiency anemia. American Journal of Clinical Nutrition. 1990;52(5):813-819.
20. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.